FiercePharma13d
Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay
Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...
STAT13d
Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more
A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...
Investing14d
Citi reiterates Apellis stock as a 'BUY' on transformative pegcetacoplan data
The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.
pharmaphorum14d
Astellas pulls geographic atrophy drug filing in the EU
Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...
Investing14d
Citi reiterates Apellis stock as a 'BUY' on transformative pegcetacoplan data
The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...
Business Insider16d
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Following this 26-week randomized controlled period, patients are able to proceed to a 26-week open-label phase in which all patients receive pegcetacoplan. The primary endpoint of the study was ...
Business Insider17d
Apellis initiated with a Sector Perform at RBC Capital
RBC Capital analyst Lisa Walter initiated coverage of Apellis (APLS) with a Sector Perform rating and $25 price target Complement inhibitors Syfovre and Izervay were approved for geographic ...